---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-005745"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:50:21.155317+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# VolitionRx markets oncology portfolio for out-licensing via PharmaVentures

## Summary
- Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.
- Document provides brief introduction to certain components of the oncology portfolio; no specific assets or terms disclosed.
- No revenue, deal value, or counterparty announced; no financial impact provided.

## SEC filing metadata
- accession: 0001477932-24-005745
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/0001477932-24-005745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224005745/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-005745
- JSON: https://secwatch.observer/filing/0001477932-24-005745.json
- Plain text: https://secwatch.observer/filing/0001477932-24-005745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.